Revision 1

Store at -20C

#81557

CUTL1 Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H	Endogenous	200	Rabbit	#P39880	1523

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:200

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

CUTL1 Antibody recognizes endogenous levels of total CUTL1 protein. It recognizes the p200 isoform (the full-length) and is not expected to recognize the p110 and p75 isoforms.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln639 of human CUTL1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

CUTL1 (Cut-like 1), also known as CUX1 (Cut homeobox 1) (CUX1), is a transcription factor that has been implicated in many cellular processes in different tissues, such as cell migration, neuronal differentiation, and DNA repair (1-5). CUTL1 expression and activities are altered in cancer. Research studies have shown the CUTL1 gene to be a frequent target of loss-of-heterozygocity in various cancers (6,7). On the other hand, CUTL1 expression is elevated in many cancers and is associated with shorter disease-free survival (8). These accumulating evidence suggest that decreased CUTL1 expression promote tumor initiation and increased CUTL1 expression facilitates tumor progression (9). While full-length CUTL1 is about 200 kDa (p200), short forms p110 and p75 can also be generated by proteolytic processing and alternative transcription initiation site, respectively (10, 11).

Background References

1. Rodríguez-Tornos, F.M. et al. (2016) *Neuron* 89, 494-506.
2. Ramdzan, Z.M. et al. (2015) *Oncotarget* 6, 3613-26.
3. Ramdzan, Z.M. et al. (2014) *PLoS Biol* 12, e1001807.
4. Kedinger, V. et al. (2009) *J Biol Chem* 284, 27701-11.
5. Vadnais, C. et al. (2012) *Nucleic Acids Res* 40, 4483-95.
6. McNerney, M.E. et al. (2013) *Blood* 121, 975-83.
7. Ramdzan, Z.M. and Nepveu, A. (2014) *Nat Rev Cancer* 14, 673-82.
8. Michl, P. et al. (2005) *Cancer Cell* 7, 521-32.
9. Hulea, L. and Nepveu, A. (2012) *Gene* 497, 18-26.
10. Moon, N.S. et al. (2001) *Mol Cell Biol* 21, 6332-45.
11. Goulet, B. et al. (2002) *Cancer Res* 62, 6625-33.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.